l e t t e r s Limb-girdle muscular dystrophy type 1D (LGMD1D) was linked to chromosome 7q36 over a decade ago 1 , but its genetic cause has remained elusive. Here we studied nine LGMD-affected families from Finland, the United States and Italy and identified four dominant missense mutations leading to p.Phe93Leu or p.Phe89Ile changes in the ubiquitously expressed co-chaperone DNAJB6. Functional testing in vivo showed that the mutations have a dominant toxic effect mediated specifically by the cytoplasmic isoform of DNAJB6. In vitro studies demonstrated that the mutations increase the half-life of DNAJB6, extending this effect to the wild-type protein, and reduce its protective anti-aggregation effect. Further, we show that DNAJB6 interacts with members of the CASA complex, including the myofibrillar myopathy-causing protein BAG3. Our data identify the genetic cause of LGMD1D, suggest that its pathogenesis is mediated by defective chaperone function and highlight how mutations in a ubiquitously expressed gene can exert effects in a tissue-, isoform-and cellular compartment-specific manner.
Limb-girdle muscular dystrophies (LGMDs) are a genetically and mechanistically heterogeneous group of disorders caused by dominant or recessive mutations in a number of sarcolemmal, sarcomeric, cytoplasmic and nuclear proteins 2 . Here we studied the molecular cause of a dominant LGMD in five previously reported Finnish (FF1-5) 3, 4 and two US families (DUK1047 and DUK1701) 1, 5 , as well as two previously unreported Italian families (IT1 and IT2) identified on the basis of clinical phenotypes and of the pattern of muscle involvement by magnetic resonance imaging. The pedigrees of the families are shown in Supplementary Figure 1 ; clinical findings are summarized in Supplementary Table 1 .
The disorder in the two US families was originally linked to 7q36 and classified as LGMD1D 1 . Clinical and genetic characterization of the Finnish families established linkage to the same locus and refined LGMD1D to a 3.4-Mb region containing 12 genes 3, 4 . Sequencing of the positional candidates RNF32, UBE3C, DNAJB6 and PTPRN2 identified a c.279C>G (p.Phe93Leu) change in exon 5 of DNAJB6 in all 16 affected individuals in the Finnish families FF1-5 (nucleotide and protein numberings based on RefSeq records NM_005494.2 and NP_005485.1, respectively). The mutation was absent from 12 unaffected individuals in these families ( Table 1 and Supplementary  Figs. 1 and 2) . Sequencing of muscle cDNA from two affected Finnish individuals confirmed that wild-type and mutant alleles were both expressed ( Supplementary Fig. 2 ). Analysis of DNAJB6 in the two US families identified a c.267T>A (p.Phe89Ile) mutation in all 29 affected individuals ( Table 1 ) and in two individuals who were of unknown disease status (as they were below the highest age of onset identified previously in the families). Two DNAJB6 mutations were identified in the Italian families-c.279C>A (IT1; eight cases) and c.277T>C (IT2; four cases)-both causing the same p.Phe93Leu change as the Finnish mutation ( Table 1) . Six available unaffected individuals in IT1 and four in IT2 had no mutations. None of the mutations were found in control chromosomes from 202 Finnish, 104 Italian or 215 US individuals. The presence of independent mutations and their segregation with the phenotype in nine families provides conclusive evidence that DNAJB6 is the causative gene for LGMD1D. DNAJB6 (also known as mammalian relative of DnaJ (MRJ)) belongs to the J proteins (also known as the heat-shock protein 40 (Hsp40) family), a class of co-chaperones characterized by a J domain. These co-chaperones interact with chaperones of the HSPA (Hsp70) Mutations affecting the cytoplasmic functions of the co-chaperone DNAJB6 cause limb-girdle muscular dystrophy l e t t e r s family, increasing and modulating their activity 6 . Some J proteins, including DNAJB6, also have HSPA-independent functions 6, 7 .
DNAJB6 is composed of a conserved N-terminal J domain, a G/F domain rich in glycine and phenylalanine residues and a C-terminal domain containing a serine-rich ("SSF-SST") region 7, 8 ( Supplementary Fig. 2a ). The J domain interacts with the constitutively expressed chaperone HSPA8 (also known as Hsc70 or Hsp73) 9 . The SSF-SST region has been shown to be important for interactions with the transcription factor NFATc3 (ref. 10) and histone deacetylases (HDACs) 7 and for DNAJB6 oligomerization 7 . The G/F domain has been suggested to participate in recognition of partially unfolded client proteins in bacterial DnaJ [11] [12] [13] and yeast Sis1 (ref. 14) . Notably, human DNAJB6 has two known isoforms characterized by alternative C termini 15 . The long isoform DNAJB6a (36 kDa) localizes to the nucleus, whereas the short isoform DNAJB6b (27 kDa) is cytoplasmic 15, 16 .
DNAJB6 has been reported to suppress aggregation and toxicity of aggregationprone proteins such as polyglutaminecontaining huntingtin and α-synuclein 7, 8, 17 and to participate in autophagic and proteasomal turnover of proteins and organelles 18, 19 , as well as in regulation of gene expression 10 and cell cycle 20 . The inhibition of aggregateinduced cytotoxicity may involve myeloid leukemia factor 1 (MLF1), which interacts with DNAJB6 and colocalizes with it in aggregates 21 . DNAJB6 is expressed in all tissues 22 , with the highest expression in brain 8 , but its expression and localization in skeletal muscle have not been characterized previously. Immunofluorescence microscopy showed DNAJB6 primarily in Z-disks in both control (not shown) and LGMD1D muscle samples ( Fig. 1a) . Electron microscopy of LGMD1D patient muscle showed Z-disk myofibrillar disintegration ( Fig. 1b) . We also observed autophagic rimmed-vacuolar degenerative pathology by electron microscopy ( Fig. 1b and Supplementary  Fig. 3 ), LC3 immunohistochemistry and Herovici staining ( Fig. 1c) . Immunofluorescence microscopy of patient muscle showed DNAJB6 in protein accumulations together with its known ligands MLF1 (ref. 21 ) and HSPA8 (ref. 9) ( Fig. 1d and Supplementary Fig. 4 ). We also observed myotilin, desmin, αB-crystallin and, occasionally, npg l e t t e r s filamin-proteins that typically aggregate in myofibrillar myopathiesin these structures. Furthermore, some accumulations stained positive for keratin 18 (KRT18), a reported client protein of DNAJB6 (ref. 9; Fig. 1d and Supplementary Fig. 4 ). Notably, we did not observe accumulation of thick and thin filament components such as myosins and actin (data not shown). For comparison, we examined muscle tissue from an individual with myofibrillar myopathy caused by a p.Ser60Cys alteration in myotilin, characterized by aggregation of myotilin and other proteins 23 . We found colocalization of DNAJB6, MLF1 and KRT18 with myotilin in these aggregates ( Supplementary  Fig. 4) . In LGMD1D muscle, DNAJB6 appeared more in the periphery of the protein accumulations, in contrast to the more pronounced colocalization seen in myotilinopathy.
To gain further insights into DNAJB6 function, we examined its role in muscle integrity in zebrafish. Reciprocal BLAST identified a single zebrafish DNAJB6 ortholog (dnajb6b). Using RT-PCR, we detected its expression as early as the embryonic five-somite stage (data not shown). Next, we injected two-cell embryos with a splice-blocking morpholino (sb-MO) targeting dnajb6b. Masked scoring of embryos at 48 h after fertilization (h.p.f.) showed a reproducible muscle fiber detachment phenotype concomitant with the splice-blocking efficiency, as established by RT-PCR ( Supplementary Fig. 5a ). Detachment of slow fibers from their insertion sites at the vertical myoseptum was evident as early as 2 d after fertilization (d.p.f.) ( Fig. 2) , suggesting that the fiber termini in morphants are prone to adhesion failure soon after mechanical load is applied by the onset of strong contraction 24 . The phenotype was specific because it was reproduced with a second non-overlapping MO (data not shown) and rescued with co-injection of wild-type human DNAJB6b mRNA (Fig. 2j) . These data suggest that loss of DNAJB6 function leads to defects in muscle integrity.
To understand the mechanistic effect of LGMD1D-associated mutations, we introduced the p.Phe93Leu and p.Phe89Ile changes into human transcripts encoding each of the two isoforms and injected them into zebrafish embryos. In contrast to wild-type DNAJB6, which yielded no appreciable defects, injection of equivalent doses of either p.Phe93Leu or p.Phe89Ile mRNAs phenocopied the loss-of-function effects of the dnajb6b sb-MO ( Fig. 2) . Strikingly, these phenotypes were generated exclusively upon injection of mutant DNAJB6b; neither mutation had any impact when engineered into DNAJB6a (Fig. 2) .
All identified LGMD1D-associated mutations map to the G/F domain of DNAJB6. Both substituted phenylalanine residues are highly conserved in DNAJB6 orthologs, and Phe93 is also conserved in several paralogs ( Supplementary Fig. 2) . Three of the four LGMD1D-causing mutations affect the same codon, causing the identical p.Phe93Leu change. To determine whether the loss of phenylalanine or the introduction of leucine is more important, we replaced Phe93 with either alanine or glycine. Embryos injected with p.Phe93Ala or p.Phe93Gly mRNA showed muscle fiber detachment similar to the p.Phe93Leu-induced phenotype (Fig. 2) , indicating that loss of Phe93 is sufficient for pathogenesis. However, the zebrafish ortholog contains a glycine instead of phenylalanine residue at position 89, suggesting that some changes might be tolerated at this position; expression of human p.Phe89Gly DNAJB6b in zebrafish embryos did not cause a muscle phenotype (Fig. 2) .
Next, we tested whether the LGMD1D mutations could be rescued with wild-type DNAJB6. Co-injection of equimolar amounts of p.Phe93Leu and wild-type mRNA into zebrafish embryos showed enhanced severity of the muscular phenotype: in comparison to 15% of embryos injected with mutant DNAJB6b alone, 42% of co-injected embryos had severe defects in muscle integrity by 2 d.p.f. (P = 0.0004; Fig. 3a) . We observed a similar effect with the p.Phe89Ile mutation (P = 0.0002; Fig. 3a) . Taken together, our data indicate that the phenotype is driven by dysfunction of the cytoplasmic isoform and suggest that the LGMD-causing mutations probably exert a deleterious dominant effect on the wild-type protein. Consistent with this notion, altering the molar ratios of mutant and wild-type mRNA had the expected effects on the phenotype: an excess of mutant mRNA compared to wild-type mRNA induced lethality in embryos, whereas an excess of wild-type mRNA compared to mutant mRNA gave rise to progressively increased rescue (Supplementary Fig. 5c ).
We next performed in vitro experiments. On the basis of evidence from the closely related DNAJB8 protein, DNAJB6 has been suggested to form oligomeric complexes 7 . As interference with complex formation could explain the dominant effect of the mutations, we studied oligomerization of wild-type and p.Phe93Leu DNAJB6b in COS-1 cells. In co-immunoprecipitation (co-IP) experiments, V5-tagged DNAJB6b pulled down the untagged construct, demonstrating oligomerization ( Supplementary Fig. 6a ), and this was unaffected by the p.Phe93Leu alteration. Likewise, in sucrose density gradient centrifugation, the distribution of wild-type and mutant proteins was similar (Supplementary Fig. 6b ). Hence, the p.Phe93Leu substitution did not significantly alter the oligomerization properties of DNAJB6. The detachment of myofibers from the myoseptum can be partial (a,b,g,h; white arrowheads) or complete (i, white asterisk). Scale bar, ~50 µm. (j) Embryos injected with the indicated constructs were categorized phenotypically based on the presence of muscle fiber detachment affecting 1-2 somites (class I, mild) or multiple somites (class II, severe; see supplementary Figure 5 for an example). The phenotype in dnajb6b MO-injected embryos was rescued efficiently by wt human DNAJB6b mRNA (χ 2 test). We next considered the possibility that LGMD1D mutations might alter DNAJB6 half-life, as we observed that cells transfected with DNAJB6b showed an increase in mutant protein abundance with no appreciable changes in mRNA levels (data not shown). To examine this, we transfected 293FT cells, blocked protein synthesis with cycloheximide (CHX) and quantified the amount of remaining protein as a function of time ( Fig. 3b and Supplementary Fig. 7 ). Both p.Phe93Leu and p.Phe89Ile considerably decreased the turnover rate of DNAJB6. To explore whether the increased abundance of mutant DNAJB6 might be proteasome or autophagosome dependent, we treated DNAJB6-transfected cells either with a proteasome poison (lactacystin) or a lysosome inhibitor (bafilomycin A1). Suppression of the proteasome had no appreciable effects on the clearance of DNAJB6. By contrast, bafilomycin treatment (in the presence of CHX) led to a significant (40-50%; P = 0.011 at 4 h, 0.0078 at 6 h) increase of DNAJB6, suggesting that DNAJB6 is at least partly cleared by the autophagosome pathway (Supplementary Fig. 7) . This is also consistent with the observation that DNAJB6 abundance was reduced in the presence of both lactacystin and CHX (compared to CHX alone), as suppression of the proteasome has been reported to enhance autophagy [25] [26] [27] .
The ability of mutant DNAJB6 to oligomerize, the increased abundance of mutant protein and the exacerbation of the zebrafish phenotypes by co-injection of wild-type mRNA suggested that mutant DNAJB6 might affect the entire oligomeric complex. To assess this, we co-transfected cells with mutant and wild-type DNAJB6b. Not only did the mutant protein decrease the turnover rate of the wild-type protein, but the stability of the mutant itself increased further in the presence of wild-type DNAJB6 (Fig. 3b) . These data confirm that mutant DNAJB6 can exert a dominant effect on the wild-type protein.
A possible explanation for the increased abundance of mutantwild type protein complexes would be formation of aggregates. However, we did not detect any increased aggregation propensity of the mutants in cell fractionation, sucrose density gradient centrifugation or immunofluorescence microscopy of transfected cells (data not shown). Hence, primary aggregation of DNAJB6 is unlikely to underlie the pathogenesis of LGMD1D. This is in line with the muscle pathology, which showed DNAJB6 in the periphery of the protein accumulations rather than in the center.
DNAJB6 has been shown to suppress aggregation of various proteins in cell culture models 7, 8, 28 . To investigate the effect of the mutations on the anti-aggregation function, we tested the ability of wild-type and mutant DNAJB6b to inhibit aggregation of polyglutaminecontaining huntingtin (pEGFP/HD-120Q) in a filter-trap assay. The nuclear DNAJB6a isoform, known to be inefficient in inhibiting cytoplasmic huntingtin aggregation 7 , served as negative control. Wild-type DNAJB6b efficiently suppressed huntingtin aggregation, as demonstrated by a decrease in the aggregate amount and a concomitant increase in SDS-soluble huntingtin ( Fig. 4 and Supplementary  Fig. 8) . In contrast, mutant constructs showed significantly impaired anti-aggregation function, although they still retained some activity. This compromised function could impair protein quality control in LGMD1D muscle, leading to protein accumulation.
Chaperone-assisted selective autophagy (CASA), mediated by a complex containing HSPA8, HSPB8 (also known as Hsp22), and the co-chaperones BAG3 and STUB1 (also known as C terminus of Hsc70interacting protein (CHIP)), is important for Z-disk maintenance 29, 30 . Several pieces of evidence prompted us to investigate the link between DNAJB6 and CASA. First, DNAJB6 is a known co-chaperone of HSPA8 Figure 3 Dominant effect of mutant DNAJB6 proteins. (a) Co-injection of wt DNAJB6b mRNA with p.Phe93Leu or p.Phe89Ile mutant mRNA in zebrafish embryos led to a more severe muscle phenotype, with a statistically significant increase in the number of class II embryos (χ 2 test). (b) DNAJB6b constructs were expressed in 293FT cells, and protein synthesis was blocked by cycloheximide (CHX). Wholecell extracts were obtained at the indicated time points and analyzed by protein blotting. DNAJB6 band intensities were quantified and normalized to α-tubulin (single transfections) or HSP90 (cotransfections) intensity to obtain the relative DNAJB6 levels. In single transfections (solid lines), CHX treatment rapidly decreased wt DNAJB6b protein levels, whereas p.Phe89Ile and p.Phe93Leu mutant proteins showed reduced turnover. In co-transfections of HA-and GFP-tagged wt and p.Phe93Leu mutant constructs (dashed lines), the wt DNAJB6b level remained stable after 4 h of CHX treatment. Data from three independent experiments are presented as mean ± s.d. Relative DNAJB6 level at t = 0 h was set to 100 for each construct. Representative protein blots are shown in supplementary Figure 7 . npg l e t t e r s (ref. 8) . Second, the pathology of LGMD1D muscle suggests defective Z-disk maintenance. Third, both DNAJB6 and the CASA complex localize to the Z-disk. Finally, mutations in BAG3 cause a myofibrillar myopathy with protein accumulations and autophagic pathology 31 .
To study a possible association of DNAJB6 with the CASA complex, we performed co-IP studies of endogenous and transfected proteins in COS-1 cells and observed interaction of DNAJB6b with BAG3, HSPB8 and STUB1 ( Fig. 5a and Supplementary Fig. 9 ). Association of DNAJB6 with the CASA machinery was also supported by in situ proximity ligation assay studies on rat muscles (Fig. 5b) . None of the interactions seemed to be affected by the p.Phe93Leu mutation ( Fig. 5a and Supplementary Fig. 9 ), indicating that the phenotype is unlikely to be caused by impaired binding of DNAJB6 to the CASA complex. The interaction with DNAJB6 suggested a possible role for BAG3 in LGMD1D and implied a pathomechanistic link between LGMD1D and the BAG3 myopathy. We therefore asked whether BAG3 could modulate the phenotype caused by mutant DNAJB6b in zebrafish. Injection of wild-type BAG3 mRNA alone caused no observable phenotype, whereas its co-injection with DNAJB6b p.Phe93Leu mRNA dramatically accentuated the muscle defect (P = 0.02; Fig. 5c ). In addition, injection of the BAG3 myopathy mutant (p.Pro209Leu) 31 alone led to a phenotype comparable to that of DNAJB6 mutants, whereas its co-injection with DNAJB6b p.Phe93Leu mRNA did not have an additive effect. These findings suggest that BAG3 has a role in mediating the pathogenic effect of DNAJB6 mutations and probably lies downstream of DNAJB6.
We describe here the first known human mutations affecting the ubiquitously expressed, multifunctional co-chaperone DNAJB6.
This protein has been implicated in a variety of degenerative disorders such as Parkinson's 17 and Huntington's 8 diseases, as well as cancer 16 . Notably, the DNAJB6 mutations we identified cause a tissue-specific disease (muscular dystrophy); despite high expression of DNAJB6 in brain, there are no indications of neurological involvement [3] [4] [5] .
The four LGMD1D mutations affect two highly conserved, closely spaced phenylalanine residues in the G/F domain. The mutations impair the anti-aggregation activity of DNAJB6b and interfere with turnover of both mutant and wild-type DNAJB6b. The unexpected finding that addition of wild-type DNAJB6b exacerbates the muscular phenotype induced by each mutation in zebrafish suggests that incorporation of mutant protein into the DNAJB6 oligomer probably confers a dominant toxic function on the entire complex. Moreover, the interaction of BAG3 with DNAJB6 and its aggravating effect on the zebrafish phenotype suggest a role for BAG3 in the pathomechanism. The myofibrillar disintegration with protein accumulations in LGMD1D muscle could reflect impaired function of the CASA machinery, leading to insufficient maintenance of sarcomeric structures or defective clearance of misfolded sarcomeric proteins.
The DNAJB6 mutations cause a dominant, late-onset muscle disease characterized by abnormal protein accumulations and autophagic pathology. Although the mutations alter the sequence of both nuclear and cytoplasmic DNAJB6, they affect muscle pathology exclusively through the cytoplasmic isoform. This is reminiscent of the mechanism proposed for Lafora progressive myoclonus epilepsy, in which mutations in EPM2A are expressed in both the nucleus and the cytoplasm but seem to interfere specifically with its cytoplasmic phosphatase activity 32 . The literature contains few other such PLA signals (red dots) indicated spatial proximity of DNAJB6 with its known interaction partner HSPA8, and with the CASA complex proteins BAG3, HSPB8 and STUB1. Negative control experiments were performed with DNAJB6 or BAG3 antibodies alone. Each image shows a representative maximum-intensity projection through a z stack of 6.4 µm, with the PLA signal (red) superimposed on the phalloidin counterstain (gray). Scale bar, 5 µm. (c) Co-injection of DNAJB6 and BAG3 in zebrafish. Zebrafish embryos were injected with DNAJB6b p.Phe93Leu mRNA and wild-type (wt) or p.Pro209Leu mutant BAG3 mRNA in indicated combinations. Co-injection of wild-type BAG3 with mutant DNAJB6 resulted in a more severe phenotype than mutant DNAJB6 alone, reflected by a significant increase in class II embryos. In contrast, co-injection of p.Pro209Leu BAG3 with mutant DNAJB6b did not alter the phenotype distribution. Statistical significance (χ 2 test) is denoted by P value or n.s. (not significant). Scale bar, ~50 µm.
npg l e t t e r s examples, despite the documented prevalence of alternative splicing 33 . Elucidation of the mechanisms by which certain isoforms of ubiquitously expressed mutant proteins can lead to organ-specific effects will be important for understanding genetic diseases and for developing therapeutic options.
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